Can providing information about a generic medicine switch reduce side effect reporting?

Not Applicable

• Conditions: Patients taking lamotrigine for epilepsy; Patients taking lamotrigine for bipolar disorder; Mental Health - Other mental health disorders; Neurological - Epilepsy

• Registration Number: ACTRN12619000654156
• Lead Sponsor: Professor Keith Petrie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-05-01
• Last Update Posted: 15 July 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

Participants must be a patient of Green Cross Health - a New Zealand provider of primary care services. They must be taking either Lamictal or Arrow-lamotrigine before the medicine change. They must have a mobile phone number on file in the Green Cross database.

Exclusion Criteria

Are taking Logem before the switch (i.e. will not be switching medicine brands) and do not have a mobile phone number in the Green Cross database

Study & Design

• Study Type: Interventional
• Study Design: Not specified